NICE issues final guidance for Servier's Protelos and BMS/Otsuka's Abilify
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has issued two pieces of final guidance both of which confirmed the final draft guidance issued in December: on Bristol-Myers Squibb/Otsuka Pharmaceuticals' Abilify (aripiprazole), for treating young people with schizophrenia, and on Servier's Protelos (strontium ranelate) for preventing osteoporotic fractures.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.